Home » Newsletters » BioWorld

BioWorld

April 5, 1994

View Archived Issues

CALGENE SEEKS USDA APPROVAL OF ITS CANOLA

T CELL SCIENCES, SMITHKLINE HALT CLINICAL TRIAL

AGRIDYNE HAS TWO PATENTS ALLOWED, GETS SBIR GRANT

JAPANESE FIRM LICENSES CHIRON RNA PROBE

LOOK-ALIKE AUTOIMMUNE ANTIBODIES BLOCK HIV

BIOTECHNOLOGY STOCK PERFORMANCE FOR FIRST QUARTER 1994

INTERNEURON'S STROKE DRUG BEGINS PHASE II/III TRIALS

ALKERMES BEGINS RMP-7 TRIALS

APPOINTMENTS AND ADVANCEMENTS

IMMUNEX FILES NEW SUPPLEMENTAL PLA FOR LEUKINE

TO OUR READERS

HEMOSOL FILES IND FOR RED BLOOD CELL SUBSTITUTE

NEORX'S INFRINGEMENT SUIT GOES ON

MAGAININ'S MSI-78 FOR IMPETIGO DEALT A SETBACK

TEACHING CELLS TO MAKE THEIR OWN ANTI-AIDS INTERFERON

GENEMEDICINE FILES FOR IPO

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 13, 2026.
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
AAIC 2026: Age of amyloid is being joined by time of tau
BioWorld
The Alzheimer’s Association International Conference (AAIC) is the world’s biggest dementia conference. And at the AAIC 2026 meeting, there is big buzz around...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
NRF2 activators reported in Vailima Peninsula patent
BioWorld Science
Vailima Peninsula Pty Ltd. has discovered new nuclear factor erythroid 2-related factor 2 (NFE2L2; NRF2) activators potentially useful for the treatment of...